Biogen (BIIB) Competitors

Regeneron Pharmaceuticals (NASDAQ:REGN) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, community ranking, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

Which has higher earnings and valuation, REGN or BIIB?

Regeneron Pharmaceuticals has higher revenue and earnings than Biogen. Biogen is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.09B	4.54	$4.41B	$39.28	15.08
Biogen	$9.82B	1.91	$1.63B	$10.13	12.62

Do institutionals and insiders believe in REGN or BIIB?

83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are held by company insiders. Comparatively, 0.2% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Do analysts recommend REGN or BIIB?

Regeneron Pharmaceuticals presently has a consensus price target of $890.60, suggesting a potential upside of 50.36%. Biogen has a consensus price target of $191.30, suggesting a potential upside of 49.60%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Regeneron Pharmaceuticals is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	19 Buy rating(s)	3 Strong Buy rating(s)	2.92
Biogen	0 Sell rating(s)	20 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.38

Which has more risk & volatility, REGN or BIIB?

Regeneron Pharmaceuticals has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.12, indicating that its stock price is 88% less volatile than the S&P 500.

Does the media refer more to REGN or BIIB?

In the previous week, Regeneron Pharmaceuticals had 25 more articles in the media than Biogen. MarketBeat recorded 55 mentions for Regeneron Pharmaceuticals and 30 mentions for Biogen. Biogen's average media sentiment score of 1.32 beat Regeneron Pharmaceuticals' score of 1.31 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	33 Very Positive mention(s)	3 Positive mention(s)	13 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Positive
Biogen	25 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community prefer REGN or BIIB?

Biogen received 264 more outperform votes than Regeneron Pharmaceuticals when rated by MarketBeat users. Likewise, 71.28% of users gave Biogen an outperform vote while only 66.95% of users gave Regeneron Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Regeneron Pharmaceuticals	Outperform Votes 1560 66.95%	Underperform Votes 770 33.05%
Biogen	Outperform Votes 1824 71.28%	Underperform Votes 735 28.72%

Is REGN or BIIB more profitable?

Regeneron Pharmaceuticals has a net margin of 31.07% compared to Biogen's net margin of 16.87%. Regeneron Pharmaceuticals' return on equity of 16.32% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	31.07%	16.32%	12.76%
Biogen	16.87%	14.98%	8.76%

Summary

Regeneron Pharmaceuticals beats Biogen on 15 of the 19 factors compared between the two stocks.